

RESEARCH PROGRAM WITH UNIVERSITY OF MIAMI HEALTH SYSTEM TO ADVANCE BREAKTHROUGH LUNG TECHNOLOGY

- 4DMedical and University of Miami Health System will establish the Functional Lung Imaging Research Program to advance breakthrough lung technologies
- This is 4DMedical's first research program in the U.S. and will use the Company's proprietary XV
 Technology™ to improve assessment and outcomes for patients with chronic lung diseases
- The research program will comprise of preclinical and clinical studies and allow physicians to have a targeted approach to the therapeutic options available to patients, driven by information available using XV Technology™
- It is expected that this research program will be another driver of acceptance and adoption of XV Technology™ at hospitals and clinics located in the U.S.

2 December 2020: 4DMedical Limited (ASX:4DX, "4DMedical" or the "Company"), a medical technology company focused on commercialising its patented respiratory imaging platform, is pleased to announce that it has partnered with University of Miami Health System ("UHealth") to establish the Functional Lung Imaging Research Program within the Miller School of Medicine.

The Functional Lung Imaging Research Program, 4DMedical's first research program in the U.S. health system, will use the Company's proprietary XV Technology™ to improve treatment outcomes for patients with chronic lung diseases. More specifically it will allow researchers and physicians to accurately diagnose ventilatory abnormalities in patients, therefore providing treatment and management options that are targeted and more effective.

This research program is expected to deliver a number of preclinical and clinical studies that will include patients with various lung-related conditions, such as emphysema, cystic fibrosis, pulmonary hypertension, pulmonary embolism and lung cancer.

The research program will fall within the Division of Pulmonary, Critical Care and Sleep Medicine.

Andreas Fouras, Founder & CEO of 4DMedical said:

"4DMedical is thrilled to partner with UHealth and the Miller School of Medicine on an initiative that provides huge potential for positive impact – from preclinical research, clinical trials and clinical piloting of our FDA 510(k) cleared, XV LVAS. The leadership and commitment of UHealth to XV Technology™ will help identify immediate use cases and novel applications for our technology."

Utilising the Company's XV Technology™ platform, XV LVAS converts sequences of X-ray images into four-dimensional quantitative data, allowing physicians to better diagnose and treat patients with respiratory diseases.

Supported by more than 15 years of development in Australia, 4DMedical's XV Technology™ improves the capacity of physicians to diagnose and treat patients with respiratory diseases more efficiently, by providing objective measurements of regional lung motion and air flow.

Henri Ford, M.D., M.H.A., Dean and Chief Academic Officer of the Miller School of Medicine said:

"Working with 4DMedical exemplifies our commitment to harness innovative technology in the quest for comprehensive treatment options for our patients. Effective treatment protocols require an accurate understanding of the disease's presentation. We plan to add 4DMedical's XV Technology™ to help us gather and apply foundational medical information required to deliver customized and effective therapies for those suffering from chronic lung diseases."

ENDS

Authorised by the 4DMedical Board of Directors.

Contacts:

Corporate Investor Media

Charlene Stahr Simon Hinsley Matthew Wright
Company Secretary + 61 401 809 653 + 61 451 896 420

companysecretary@4dmedical.com shinsley@4dmedical.com matt@nwrcommunications.com.au

About University of Miami Health System & Miller School of Medicine:

The University of Miami Health System (UHealth) delivers leading-edge patient care by the region's best doctors, powered by the groundbreaking research and medical education of the University of Miami Leonard M. Miller School of Medicine. As South Florida's only academic health system, UHealth is a vital component of the community.

UHealth combines patient care, research, and education to create a front-line approach to health care. Within the UHealth system, patients can participate in clinical trials and benefit from the latest developments that are fast-tracked from the laboratory to the bedside.

UHealth's comprehensive network includes three hospitals, more than 30 outpatient facilities in Miami-Dade, Broward, Palm Beach, and Collier counties, with more than 1,300 physicians and scientists.

About 4DMedical:

Based in Melbourne, Australia and Los Angeles, USA, 4DMedical (formerly 4Dx) was founded in 2012 and is listed on the Australian Securities Exchange (ASX: 4DX).

4DMedical is a medical technology company aiming to deliver the global gold standard in respiratory diagnostics for all lung disorders including: coronavirus, asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis and cancer.

The unique 4DMedical technology accurately and quickly scans lung function as the patient breathes, to assist in providing sensitive, early diagnosis, and to monitor changes over time. Our Software-as-a-Service (SaaS) scans deliver much more complete results, showing even subtle variations in lung function down to the finest details, using lower levels of radiation than traditional methods.

Respiratory diagnosis is a US\$31 billion per annum global industry. Through its technology 4DMedical provides clinicians with greater insights into diseases of the lung. 4DMedical is focused on providing better information to doctors and patients about lung function. Better information means better decisions, and better outcomes.